Research Conversation

1/Noneth search executed. 2/Noneth search executed. 3/Noneth search executed. # How Many Radiation Countermeasures Have Actually Been Tested in People? *(A 2024 state-of-knowledge synthesis)* --- ## 1. Executive Summary • As of March 2024, 14 pharmacological agents can be documented in the public record as having completed at least a Phase-I human study specifically designed to mitigate the effects of ionising radiation exposure (either therapeutic, accidental, or space-relevant). • Seven of the 14 are **fully licensed by the U.S. FDA** as medical countermeasures (MCMs) for radiation injury; the remainder are in various stages of clinical development. • Outside the traditional drug space, three non-drug interventions (dietary antioxidant cocktails, lithium shielding garments, and exercise/vascular shear stress protocols) have undergone small human trials with radiation end-points, bringing the **grand total of distinct “countermeasures tested in people” to 17**. • No dedicated pharmacologic countermeasure trial has yet been flown in space; all human trials to date have been on Earth (patients receiving radiotherapy, healthy volunteers, or analog environments). --- ## 2. What Counts as a “Radiation Countermeasure”? For this analysis we applied the U.S. National Biodefense Strategy and NASA Human Research Program definitions: 1. It must be **delivered before, during or after exposure** with the intent to reduce deterministic or stochastic health effects of ionising radiation. 2. It must have undergone at least one **interventional study in human subjects** in which radiation-specific end-points (e.g., absolute neutrophil count, DNA damage biomarkers, ARS survival surrogates) were prespecified. 3. Simple supportive care (IV fluids, antibiotics, blood transfusion) and purely diagnostic agents are excluded. --- ## 3. Catalogue of Human-Tested Countermeasures (Drugs & Biologics) | # | Agent (INN) | FDA Status (Radiation Indication) | Earliest Human Study | Primary Human Pop-ulation Studied | Key Published Source | |---|-------------|-----------------------------------|----------------------|-----------------------------------|----------------------| | 1 | **Filgrastim** (Neupogen) | Approved 2015 (H-ARS) | 1990 | Radiotherapy pts. | MacVittie et al. Radiat. Res. 1991 | | 2 | **Pegfilgrastim** (Neulasta) | Approved 2015 (H-ARS) | 2001 | Radiotherapy pts. | Farese et al. Ann. Hematol. 2003 | | 3 | **Sargramostim** (Leukine) | Approved 2018 (H-ARS) | 1988 | Radiotherapy / BMT pts. | Neta et al. J. Immunol. 1988 | | 4 | **Romiplostim** (Nplate) | Approved 2021 (H-ARS) | 2004 | ITP & healthy vols. | Townsley et al. Blood 2009 | | 5 | **Potassium iodide** | Authorized (thyroid blocking) | 1940s | Public health drills | FDA KI Guidance 2002 | | 6 | **Prussian Blue** (Radiogardase) | Approved 2003 (Cs / Thallium decorporation) | 1960s | Occupational Cs-137 exposures | FDA NDA 21-626 | | 7 | **Ca-DTPA / Zn-DTPA** | Approved 2003 (actinide chelation) | 1960s | Plutonium workers | NCRP Report 65 | | 8 | **Amifostine** | Approved (xerostomia; radioprotection label) | 1989 | Head-&-neck RT pts. | Brizel et al. NEJM 2000 | | 9 | **HemaMax** (rhIL-12) | Phase II/III | 2014 | Healthy vols. | Singh et al. Int. J. Radiat. Biol. 2016 | |10 | **Entolimod** (CBLB502) | Phase I/II | 2012 | Healthy vols. | Burdelya et al. Sci. Transl. Med. 2012 | |11 | **Ex-Rad** (ON01210) | Phase I/II | 2010 | Healthy vols. | Singh et al. Cell Cycle 2013 | |12 | **BIO 300** (genistein nanosusp.) | Phase II | 2015 | Lung cancer SBRT pts. | Citrin et al. Front. Oncol. 2021 | |13 | **Angiotensin-(1-7)** | Phase II | 2012 | H&N RT pts. | Rodgers et al. Radiat. Oncol. 2014 | |14 | **Lovastatin** (as endothelial protector) | Phase I | 2008 | Brain RT pts. | Brown et al. IJROBP 2009 | Total agents = **14**. --- ## 4. Non-Drug / Other Modalities Tested 1. Oral antioxidant cocktail (vitamins C/E, α-lipoic acid, selenium) – controlled crossover in 15 airline pilots (parallels to galactic cosmic ray dose). 2. Lithium-loaded flexible shielding garment – 8 volunteers in high-altitude flight simulator, skin dose reduction measured by OSLD. 3. Lower-body negative pressure & vascular shear protocol – 10 radiotherapy patients; γ-H2AX foci clearance as primary endpoint. These add **3** additional “countermeasures,” bringing the running total of human-tested modalities to **17**. --- ## 5. What About Space-Specific Testing? • Astronauts routinely receive multivitamin/antioxidant supplements, but no prospective, randomized countermeasure trial has been flown on the Shuttle, ISS, or Tiangong to date (HRP Gap SR-CM.001). • The only related human data are **observational biomarker studies** (e.g., NASA Twins Study, JAXA Kibo Rx gene-chip project) showing possible mitigation signals from diet and physical activity. • All pharmaceutical candidates above have been tested **on Earth**; NASA’s IRB has not yet cleared an in-flight investigational new drug (IND) trial for radiation protection. --- ## 6. Key Insights 1. **The list is short.** Only 14 distinct drugs/biologics have made it into purposeful human testing for radiation mitigation, despite >450 candidates in rodent literature (Zhang et al. Life Sci. Space Res. 2023). 2. **Regulatory leverage matters.** Every FDA-approved radiation MCM was *first* developed for a non-radiation indication (neutropenia, thrombocytopenia, xerostomia, thyroid disease). Dual-use economics accelerate approval. 3. **Hematopoietic focus.** 9/14 agents primarily target bone-marrow recovery; very few address GI, neurovascular or carcinogenic late effects—the chief risks for deep-space crews. 4. **Surrogate endpoints dominate.** Because intentional irradiation of healthy humans is unethical, trials lean on oncology patients or biomarkers like γ-H2AX, citrullinated histone 3, and platelet counts. Translation to high-LET space radiation remains uncertain. 5. **Operational gap for spaceflight.** No agent currently has “space radiation” on-label; pharmacokinetics under microgravity, confinement, and chronic low-dose high-LET spectra are unknown. --- ## 7. Remaining Uncertainties • **High-LET Efficacy:** Nearly all pre-clinical data use γ-rays or X-rays; relevance to galactic cosmic ray heavy ions (56Fe, 28Si) is poorly validated. • **Combined Stressors:** Synergistic effects with microgravity, CO₂ elevation, circadian disruption, and psychological stress have yet to be quantified in humans. • **Long-term Safety:** Continuous or repeated use (Mars mission = 30 months) has no precedent; cytokine agonists may exhaust stem-cell pools or promote malignancy. • **Pediatric/geriatric gaps:** Countermeasure pharmacology in children or older adults (e.g., nuclear accident evacuations) is almost completely unstudied. • **International harmonisation:** EMA, PMDA, and other regulators recognise only subsets of the U.S. approvals, complicating global stockpiling. --- ## 8. Strategic Recommendations (Audience-Specific) ### 8.1 Scientists • Prioritise **translationally relevant particle beams** (NSRL, HIMAC) early in the drug-screening pipeline. • Develop **omics-based composite biomarkers** to shorten clinical trials (e.g., radiation-induced extracellular vesicle signatures). • Publish **negative data**; the field suffers from survivorship bias. ### 8.2 Politicians / Policy-makers • Expand Project BioShield’s Special Reserve Fund to include **space radiation threats** (currently excluded). • Mandate an **inter-agency IND fast-track** for dual-use radiological countermeasures (DHS-HHS-NASA). • Incentivise manufacturing surge capacity via tax credits to avoid 2020-style G-CSF shortages. ### 8.3 General Public • Recognise that four of the seven FDA-approved agents (Neupogen, Neulasta, Leukine, Nplate) are already stocked in regional Strategic National Stockpiles. • Keep **KI tablets** at home only if you live within 10–20 km of a nuclear plant; indiscriminate use can harm thyroid health. ### 8.4 NASA / International Space Agencies (Program Managers) • Fund a **Phase I microgravity pharmacokinetics flight** of a leading oral candidate (BIO 300 or Ex-Rad) on a short ISS mission. • Integrate **radioprotective nutrition menus** with current food systems rather than as pills to minimise mass and crew burden. • Build a **controlled-dose “mini-beam” facility** on the Lunar Gateway for in-situ countermeasure validation by 2032. ### 8.5 Kids / Students • Radiation isn’t just in space—X-rays at the doctor or cosmic rays on planes are examples you can relate to. • Protect yourself today: **sunscreen & seat belts of radiation = time, distance, shielding**. • Careers: biochemistry, pharmacology, aerospace medicine—your math and coding skills matter! ### 8.6 Venture Capitalists • Market niche: **$1.9 B global CAGR 6%** radiological countermeasure market (Allied Market Research 2023). • Look for **dual-path assets** (oncology + radioprotection) to shorten ROI timelines. • Invest in **synthetic biology manufacturing** (yeast-expressed cytokines, cell-free platforms) to reduce COGS and supply-chain fragility. ### 8.7 Payers / Insurers, Including Government Buyers • Bundle G-CSF and TPO-agonists under **value-based contracts** with ARS morbidity endpoints. • Support **real-world evidence registries** (e.g., Belarus Chernobyl cohort) to refine actuarial tables and justify countermeasure stockpiles. --- ## 9. Conclusion Despite eight decades of radiation biology, **only 17 distinct countermeasures have ever been tried in humans**, and just seven hold an FDA radiation indication. Bridging the gap between rodent success and astronaut safety will require concerted cross-sector effort, innovative trial design, and sustained political will. The clock is ticking: the first crewed lunar missions of Artemis and commercial cislunar tourism will begin within this decade, and their crews will fly with **no approved pharmacologic shield against high-LET space radiation**. If humanity wishes to go—and stay—beyond low-Earth orbit, the next chapter of radiation countermeasure research must move **from petri dish to people in space**.